| Literature DB >> 31533678 |
Akihiro Nakane1,2, Hiroki Kubota3,4, Yusuke Noda3,4, Tomoki Takeda3,4, Yasuhiko Hirose3,4, Atsushi Okada4, Kentaro Mizuno5, Noriyasu Kawai4, Keiichi Tozawa4, Yutaro Hayashi5, Takahiro Yasui4.
Abstract
BACKGROUND: We investigated the impact of postoperative membranous urethral length and other anatomic characteristics of the pelvic floor shape as measured by magnetic resonance imaging on the improvement in continence following robotic-assisted radical prostatectomy.Entities:
Keywords: Magnetic resonance imaging; Pelvic anatomy; Robotic-assisted radical prostatectomy; Urinary incontinence
Mesh:
Year: 2019 PMID: 31533678 PMCID: PMC6751577 DOI: 10.1186/s12894-019-0519-8
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Fig. 1Postoperative pelvic anatomic features on T2-weighted magnetic resonance imaging. a Membranous urethral length measured in the sagittal plane. The dashed lines show the membranous urethra. b Levator muscle width measured in the axial plane. The dashed lines show the levator muscle. c Bladder neck width on the trigone side measured in the sagittal plane. The dashed lines show the posterior bladder neck wall
Clinical characteristics and surgical outcomes
| Patients who underwent postoperative prostate MRI ( | Patients in the whole series ( | |||
|---|---|---|---|---|
| Age (years; mean ± SD; range) | 67.9 ± 5.4 | (53–76) | 68.7 ± 4.7 | (53–76) |
| BMI (kg/m2; mean ± SD; range) | 24.1 ± 2.8 | (18.9–30.7) | 23.9 ± 2.8 | (16.8–33.4) |
| Preoperative PSA level (ng/mL; mean ± SD; range) | 9.9 ± 6.9 | (4.0–43.4) | 9.5 ± 6.6 | (4.0–57.1) |
| Clinical T stage (n, %) | ||||
| cT1 | 23 (30.3) | 148 (49.2) | ||
| pT2 | 49 (67.1) | 136 (45.2) | ||
| pT3 | 1 (1.4) | 17 (5.6) | ||
| Biopsy Gleason’s score (n, %) | ||||
| ≦ 6 | 25 (34.2) | 94 (31.2) | ||
| = 7 | 30 (41.1) | 137 (45.5) | ||
| ≧ 8 | 18 (24.7) | 70 (23.3) | ||
| Operative time (min; mean ± SD; range) | 182.3 ± 48.8 | (108–307) | 187.3 ± 44.4 | (103–313) |
| Console time (min; mean ± SD; range) | 141.0 ± 41.7 | (76–250) | 145.6 ± 41.3 | (74–289) |
| Estimated blood loss (mL; mean ± SD; range) | 98.1 ± 76.6 | (2–380) | 93.3 ± 99.4 | (1–650) |
| Prostate volume (mL; mean ± SD; range) | 50.2 ± 24.2 | (10–175) | 44.1 ± 18.9 | (10–175) |
| Pathological T stage (n, %) | ||||
| pT2 | 57 (78.1) | 226 (75.1) | ||
| pT3 | 16 (21.9) | 75 (24.9) | ||
| Positive surgical margins (n, %) | ||||
| All stages | 11 (15.1) | 62 (20.1) | ||
| pT2 | 7 (12.3) | 29 (12.8) | ||
| pT3 | 4 (25.0) | 33 (44.0) | ||
| Catheter removal period (days; mean ± SD; range) | 7.2 ± 0.8 | (6–13) | 7.5 ± 3 | (4–45) |
| Postoperative hospital stay (days; mean ± SD; range) | 10.7 ± 2.2 | (8–20) | 10.9 ± 4.9 | (7–49) |
| % continence (%) | ||||
| ≤ 1 month | 27.4 | 31.7 | ||
| ≤ 3 months | 53.4 | 51.2 | ||
| ≤ 6 months | 68.5 | 70.3 | ||
| ≤ 12 months | 84.9 | 78.8 | ||
Abbreviations: BMI Body mass index, PSA Prostate-specific antigen, SD Standard deviation
Clinical characteristics and surgical outcomes for patients based on continence recovery at 3 months
| Early continece group | Late continece group | |
|---|---|---|
| n | 39 | 34 |
| Age (years) | 68.2 ± 6.2 | 67.6 ± 4.8 |
| BMI (kg/m2) | 23.8 ± 3.0 | 23.1 ± 2.4 |
| Console time (min) | 179.0 ± 41.7 | 157.3 ± 37.8 |
| Prostate volume (mL) | 39.8 ± 12.6 | 43.7 ± 12.7 |
| Catheter removal period (days) | 7.0 ± 0.0 | 7.1 ± 0.3 |
| Postoperative hospital stay (days) | 11.3 ± 2.9 | 10.3 ± 1.4 |
Abbreviation: BMI Body mass index
Fig. 2Association between postoperative pelvic anatomic features and urinary continence after robot-assisted radical prostatectomy. Pelvic anatomic features were evaluated with magnetic resonance imaging and compared based on postoperative urinary continence. a Membranous urethral length. b Levator muscle width. c Bladder neck width on the trigone side
Multivariate logistic regression analysis results for clinical characteristics, Perioperative parameters, and MRI measurements predicting the early urinary complete continence at 3 months after RARP
| Clinical characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 0.924 | 0.841, 1.014 | 0.096 | 1.007 | 0.885, 1.146 | 0.912 |
| BMI | 1.110 | 0.932, 1.323 | 0.242 | 1.018 | 0.803, 1.290 | 0.884 |
| Clinical T stage (cT1, cT2, cT3) | 1.525 | 0.547, 4.248 | 0.420 | 2.354 | 0.469, 11.806 | 0.298 |
| Biopsy Gleason’s score ( | 0.813 | 0.456, 1.449 | 0.483 | 0.741 | 0.289, 1.904 | 0.534 |
| Perioperative parameters | ||||||
| Prostate volume | 1.003 | 0.983, 1.023 | 0.783 | 0.996 | 0.965, 1.028 | 0.807 |
| Catheter removal period | 0.843 | 0.451, 1.576 | 0.593 | 1.001 | 0.510, 1.963 | 0.999 |
| Postoperative hospital stay | 0.955 | 0.767, 1.191 | 0.685 | 0.870 | 0.654, 1.156 | 0.335 |
| Pathological T stage (pT2, pT3) | 0.589 | 0.178, 1.950 | 0.386 | 0.783 | 0.147, 4.153 | 0.773 |
| Pathological Gleason’s score ( | 0.600 | 0.314, 1.144 | 0.121 | 0.495 | 0.179, 1.368 | 0.175 |
| MRI measurements | ||||||
| MUL | 1.184 | 1.031, 1.359 | 0.017 | 1.227 | 1.011, 1.489 | 0.038* |
| BNW | 1.617 | 1.181, 2.213 | 0.003 | 1.585 | 1.050, 2.393 | 0.028* |
| LMW | 1.446 | 0.817, 2.561 | 0.205 | 1.087 | 0.486, 2.433 | 0.840 |
Abbreviations: OR Odds ratio, CI Confidence interval, BMI Body mass index, BNW Bladder neck width on the trigone side, LMW Levator muscle width, MUL Membranous urethral length
*On the multivariate analysis, MUL and BNW were associated with the period of early complete urinary continence